Somaxon Pharmaceuticals, Inc. and CJ CheilJedang Announce Silenor® Collaboration in South Korea

SAN DIEGO & SEOUL, South Korea--(BUSINESS WIRE)--Somaxon Pharmaceuticals, Inc. (Nasdaq: SOMX) and CJ CheilJedang Corporation today announced that they have entered into an exclusive collaboration under which CJ CheilJedang will commercialize Silenor® (doxepin) for the treatment of insomnia in South Korea.

MORE ON THIS TOPIC